Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - GRAFTA Nanotech Corp. (TSXV: GFTA) (the "Company") is pleased to announce that it has granted (the "Option Grant") an aggregate of 2,900,000 stock options (the "Options") to certain of its directors, officers, employees and consultants (the "Optionees") pursuant to the Company's stock option plan (the "Plan"). The Options are each exercisable into one common share of the Company (each, an "Optioned Share") at an exercise price.
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2026) - GRAFTA Nanotech Corp. (TSXV: GFTA) (formerly Wittering Capital Corp.) (the "Company") is pleased to announce that, effective August 8, 2026, the Company has engaged 17305486 Canada Ltd. (dba Ace Capital Partners) (the "Advisor") to provide capital markets advisory services to the Company (the "Advisory Engagement"). Pursuant to the terms of the advisory agreement, the Advisor will provide strategic and financial advisory services.
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - GRAFTA Nanotech Corp. (TSXV: GFTA) ("GRAFTA" or the "Company") announces that it has engaged the services of Atrium Research Corporation ("Atrium"), a company-sponsored research firm.Atrium will publish research reports on GRAFTA based on publicly available information, industry data and discussions with management. Atrium will also host two recorded interviews with GRAFTA's management team to provide additional insight into the Company, its
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.